In a pilot trial of 199 STEMI patients after primary PCI, ticagrelor alone versus ticagrelor plus aspirin gave similar 13-month MACCE (4.1% vs 4.0%; HR 1.04, underpowered). Clinically relevant bleeding 4.1% vs 10.9% (HR 0.37, 95% CI 0.12-1.17).
RCTn = 200
Yosofi et al. Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial